NASDAQ:GRCE Grace Therapeutics Q2 2027 Earnings Date & Estimates $1.95 +0.06 (+3.17%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$1.94 0.00 (-0.26%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Grace Therapeutics is estimated to report Q2 2027 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ2 2027Announcement DateNovember 12, 2026TimeBefore Market OpensConference Call DateNovember 13, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Grace Therapeutics in Q2 2027Grace Therapeutics is expected to post earnings of -$0.15 per share on revenue of $1.00 million. In the same quarter a year earlier Grace Therapeutics reported -$0.15 per share. Grace Therapeutics last reported on August 14, 2026, posting -$0.91 per share and missing the -$0.1293 consensus estimate. Grace Therapeutics has beaten the consensus EPS estimate in 4 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.15Expected Revenue$1.00 millionPrior-Year EPS-$0.15Recent Track RecordLast ReportedQ1 2027Last Quarter EPS-$0.91 (Missed by -$0.7807)EPS Beat Rate4 of last 7 quartersPrepare for the Q2 2027 CallEarnings HistoryCompany ProfileQ1 2027 Earnings ReportQ4 2026 Earnings ReportQ4 2025 Earnings Report Grace Therapeutics Q2 2027 Earnings FAQ When does Grace Therapeutics report Q2 2027 earnings? Grace Therapeutics (NASDAQ:GRCE) is estimated to report Q2 2027 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Grace Therapeutics' Q2 2027 earnings call? Grace Therapeutics' Q2 2027 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Grace Therapeutics? Analysts expect Grace Therapeutics to post earnings of -$0.15 per share for Q2 2027. How much revenue is Grace Therapeutics expected to report? The consensus revenue estimate for Grace Therapeutics is $1.00 million for Q2 2027. Grace Therapeutics Earnings HeadlinesGrace Therapeutics (NASDAQ:GRCE) Stock Rating Raised to Sell at Wall Street ZenOctober 12, 2026 | americanbankingnews.comGrace Therapeutics Shareholders Back Board, Pay and AuditorSeptember 18, 2026 | tipranks.comI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on. | Behind the Markets (Ad)Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment ConferenceSeptember 3, 2026 | globenewswire.comGrace Therapeutics, Inc.: Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business UpdateAugust 13, 2026 | finanznachrichten.deGrace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business UpdateAugust 13, 2026 | globenewswire.comSee More Grace Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email. Email Address About Grace TherapeuticsGrace Therapeutics (NASDAQ:GRCE) is a clinical-stage biopharmaceutical company focused on developing treatments for rare and serious medical conditions. The company uses proprietary drug-delivery technologies to develop pharmaceutical formulations intended to improve the administration, absorption, and clinical utility of existing or emerging therapies. Its development pipeline has included GTX-104, an investigational formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, a life-threatening type of bleeding in the brain. Grace Therapeutics has also pursued additional product candidates for rare diseases and other conditions with significant unmet medical needs. The company’s activities are centered on pharmaceutical research and development, clinical testing, and regulatory advancement rather than the sale of a broad portfolio of commercial products. Publicly available information about its leadership, geographic operations, and marketed products is limited.View Grace Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
